KOP’s Center for Breakthrough Medicines sells controlling interest to South Korean firm

The South Korean conglomerate invested $350 million in King of Prussia's Center for Breakthrough Medicines in December 2021.

Previous Northeastern to lead new infectious disease prediction center
Next RE/MAX, Anywhere Real Estate reach settlements in high-stakes lawsuit that could reshape homebuying

No Comment

Leave a reply

Your email address will not be published. Required fields are marked *